Taliansko - taliančina - myHealthbox

guna spa - serenoa repens - capsule - 40.5g - serenoa repens e vitamine - ipofertilità - integratore alimentare - spermotrend è indicato per aiutare a ridurre l’impatto negativo dello stress ossidativo sulla capacità riproduttiva maschile.

Taliansko - taliančina - myHealthbox

guna - roe extract, acido glicirretico , vitamina e , provitamina d , boswellia serrata, lecitina - crema - aqua, octyldodecanol, cetearyl alcohol, glycerin, alcohol denat., ceteareth-20, glycyrrhetinic acid, zanthoxylum alatum extraxt, roe extract, hydrogenated lecithin, boswellia serrata gum, 7-dehydrocholesterol, oleyl alcohol , glucose, dimethicone, xanthan - cosmetici - creme

Taliansko - taliančina - Ministero della Salute

medtronic sofamor danek usa, inc. - sistemi per fissazione dorso-lombo-sacrale

Taliansko - taliančina - Ministero della Salute

scandimed international a.s. - papillotomi o sfinterotomi - altri

Taliansko - taliančina - Ministero della Salute

spineart sa - sistemi per fissazione dorso-lombo-sacrale

Taliansko - taliančina - Ministero della Salute

cook incorporated - tubi medicali di raccordo

Taliansko - taliančina - Ministero della Salute

medcomp, inc. - cateteri per emodialisi permanente

Taliansko - taliančina - Ministero della Salute

medcomp, inc. - cateteri per emodialisi permanente

Taliansko - taliančina - Ministero della Salute

medcomp, inc. - cateteri per emodialisi permanente

Európska únia - taliančina - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.